Suppr超能文献

酪氨酰-DNA磷酸二酯酶I催化突变体揭示了一种可催化底物裂解的替代亲核试剂。

Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.

作者信息

Comeaux Evan Q, Cuya Selma M, Kojima Kyoko, Jafari Nauzanene, Wanzeck Keith C, Mobley James A, Bjornsti Mary-Ann, van Waardenburg Robert C A M

机构信息

From the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.

the University of Alabama at Birmingham Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294.

出版信息

J Biol Chem. 2015 Mar 6;290(10):6203-14. doi: 10.1074/jbc.M114.635284. Epub 2015 Jan 21.

Abstract

Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the repair of 3'-DNA adducts, such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA. Tdp1 contains two conserved catalytic histidines: a nucleophilic His (His(nuc)) that attacks DNA adducts to form a covalent 3'-phosphohistidyl intermediate and a general acid/base His (His(gab)), which resolves the Tdp1-DNA linkage. A His(nuc) to Ala mutant protein is reportedly inactive, whereas the autosomal recessive neurodegenerative disease SCAN1 has been attributed to the enhanced stability of the Tdp1-DNA intermediate induced by mutation of His(gab) to Arg. However, here we report that expression of the yeast His(nuc)Ala (H182A) mutant actually induced topoisomerase I-dependent cytotoxicity and further enhanced the cytotoxicity of Tdp1 His(gab) mutants, including H432N and the SCAN1-related H432R. Moreover, the His(nuc)Ala mutant was catalytically active in vitro, albeit at levels 85-fold less than that observed with wild type Tdp1. In contrast, the His(nuc)Phe mutant was catalytically inactive and suppressed His(gab) mutant-induced toxicity. These data suggest that the activity of another nucleophile when His(nuc) is replaced with residues containing a small side chain (Ala, Asn, and Gln), but not with a bulky side chain. Indeed, genetic, biochemical, and mass spectrometry analyses show that a highly conserved His, immediately N-terminal to His(nuc), can act as a nucleophile to catalyze the formation of a covalent Tdp1-DNA intermediate. These findings suggest that the flexibility of Tdp1 active site residues may impair the resolution of mutant Tdp1 covalent phosphohistidyl intermediates and provide the rationale for developing chemotherapeutics that stabilize the covalent Tdp1-DNA intermediate.

摘要

酪氨酰 - DNA磷酸二酯酶I(Tdp1)催化3'-DNA加合物的修复,例如DNA拓扑异构酶I与DNA之间的3'-磷酸酪氨酰连接。Tdp1含有两个保守的催化组氨酸:一个亲核组氨酸(His(nuc)),它攻击DNA加合物以形成共价3'-磷酸组氨酰中间体;以及一个广义酸碱组氨酸(His(gab)),它分解Tdp1 - DNA连接。据报道,His(nuc)突变为丙氨酸的突变蛋白无活性,而常染色体隐性神经退行性疾病SCAN1被认为是由于His(gab)突变为精氨酸导致Tdp1 - DNA中间体稳定性增强所致。然而,我们在此报告,酵母His(nuc)丙氨酸(H182A)突变体的表达实际上诱导了拓扑异构酶I依赖性细胞毒性,并进一步增强了Tdp1 His(gab)突变体的细胞毒性,包括H432N和与SCAN1相关的H432R。此外,His(nuc)丙氨酸突变体在体外具有催化活性,但活性水平比野生型Tdp1低85倍。相比之下,His(nuc)苯丙氨酸突变体无催化活性,并抑制His(gab)突变体诱导的毒性。这些数据表明,当His(nuc)被含有小侧链(丙氨酸、天冬酰胺和谷氨酰胺)的残基取代时,另一个亲核试剂具有活性,但被含有大侧链的残基取代时则无活性。实际上,遗传、生化和质谱分析表明,紧邻His(nuc) N端的一个高度保守的组氨酸可以作为亲核试剂催化共价Tdp1 - DNA中间体的形成。这些发现表明,Tdp1活性位点残基的灵活性可能会损害突变型Tdp1共价磷酸组氨酰中间体的分解,并为开发稳定共价Tdp1 - DNA中间体的化疗药物提供了理论依据。

相似文献

1
Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.
J Biol Chem. 2015 Mar 6;290(10):6203-14. doi: 10.1074/jbc.M114.635284. Epub 2015 Jan 21.
2
Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target.
Drug Metab Rev. 2014 Nov;46(4):494-507. doi: 10.3109/03602532.2014.971957. Epub 2014 Oct 20.
3
Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: a member of the phospholipase D superfamily.
J Mol Biol. 2012 Jan 27;415(4):741-58. doi: 10.1016/j.jmb.2011.11.044. Epub 2011 Dec 6.
4
Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.
J Mol Biol. 2007 Sep 28;372(4):1070-1081. doi: 10.1016/j.jmb.2007.07.055. Epub 2007 Aug 2.
6
Spinocerebellar ataxia with axonal neuropathy.
Adv Exp Med Biol. 2010;685:75-83. doi: 10.1007/978-1-4419-6448-9_7.
7
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1.
Nature. 2005 Mar 3;434(7029):108-13. doi: 10.1038/nature03314.
9
Tyrosyl-DNA phosphodiesterase (Tdp1) (3'-phosphotyrosyl DNA phosphodiesterase).
Methods Enzymol. 2006;409:511-24. doi: 10.1016/S0076-6879(05)09030-0.
10
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.
Oncotarget. 2016 Dec 27;7(52):86660-86674. doi: 10.18632/oncotarget.13528.

引用本文的文献

1
Zymolyase Treatment of Affects Cellular Proteins and Degrades Tyrosyl-DNA Phosphodiesterase I.
DNA Cell Biol. 2024 Jul;43(7):353-361. doi: 10.1089/dna.2024.0062. Epub 2024 Apr 29.
2
Mechanistic insight into AP-endonuclease 1 cleavage of abasic sites at stalled replication fork mimics.
Nucleic Acids Res. 2023 Jul 21;51(13):6738-6753. doi: 10.1093/nar/gkad481.
5
Altered APE1 activity on abasic ribonucleotides is mediated by changes in the nucleoside sugar pucker.
Comput Struct Biotechnol J. 2021 May 25;19:3293-3302. doi: 10.1016/j.csbj.2021.05.035. eCollection 2021.
6
Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.
Cancer Drug Resist. 2019;2(4):1153-1163. doi: 10.20517/cdr.2019.91. Epub 2019 Dec 19.
8
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.
F1000Res. 2019 Sep 30;8. doi: 10.12688/f1000research.20201.1. eCollection 2019.
9
APE1: A skilled nucleic acid surgeon.
DNA Repair (Amst). 2018 Nov;71:93-100. doi: 10.1016/j.dnarep.2018.08.012. Epub 2018 Aug 23.
10
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.
Oncotarget. 2016 Dec 27;7(52):86660-86674. doi: 10.18632/oncotarget.13528.

本文引用的文献

1
TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs.
Nucleic Acids Res. 2013 Sep;41(16):7793-803. doi: 10.1093/nar/gkt483. Epub 2013 Jun 17.
2
Structural basis for recognition of 5'-phosphotyrosine adducts by Tdp2.
Nat Struct Mol Biol. 2012 Dec;19(12):1372-7. doi: 10.1038/nsmb.2423. Epub 2012 Oct 28.
3
Mechanism of repair of 5'-topoisomerase II-DNA adducts by mammalian tyrosyl-DNA phosphodiesterase 2.
Nat Struct Mol Biol. 2012 Dec;19(12):1363-71. doi: 10.1038/nsmb.2418. Epub 2012 Oct 28.
4
Recurrent hemizygous deletions in cancers may optimize proliferative potential.
Science. 2012 Jul 6;337(6090):104-9. doi: 10.1126/science.1219580. Epub 2012 May 24.
5
Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.
J Biol Chem. 2012 Apr 13;287(16):12848-57. doi: 10.1074/jbc.M111.333963. Epub 2012 Feb 27.
6
Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: a member of the phospholipase D superfamily.
J Mol Biol. 2012 Jan 27;415(4):741-58. doi: 10.1016/j.jmb.2011.11.044. Epub 2011 Dec 6.
7
Structure of an aprataxin-DNA complex with insights into AOA1 neurodegenerative disease.
Nat Struct Mol Biol. 2011 Oct 9;18(11):1189-95. doi: 10.1038/nsmb.2146.
8
AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1.
FEBS Lett. 2011 Feb 18;585(4):683-6. doi: 10.1016/j.febslet.2011.01.032. Epub 2011 Jan 26.
9
Topoisomerases and site-specific recombinases: similarities in structure and mechanism.
Crit Rev Biochem Mol Biol. 2010 Dec;45(6):520-34. doi: 10.3109/10409238.2010.513375.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验